Jessie Desir
University of Miami, USA
Title: Hormone receptor-positive/HER2-negative mBC A brief overview of disease management from a nursing perspective
Biography
Biography: Jessie Desir
Abstract
Breast cancer (BC) represents the most frequent cancer in women and the second cause of cancer deaths worldwide. Breast cancer is the most diagnosed cancer in the United States, and its incidence rates cannot go unrecognized, especially in younger women. The human immune cells play a dual role during cancer onset and progression, contributing to tumor escape. The earlier breast cancer is diagnosed and staged, the better the chance of surviving five years after being diagnosed. BC progression is a complex process controlled by receptors that coordinate the control of tumor cells growth. Breast cancer subtypes differ in presentation, response to treatment, and outcomes. Identifying the breast cancer stage, pathology, subtype, and mutational status informs treatment options. The determination of breast cancer staging confirms the extent of the disease. The treatment strategy is to understand and know the stage, pathology, receptor status, and mutational status. Hormone receptor-positive (HR+), human epidermal growth factor receptor 2–negative (HER2-) is the most common breast cancer subtype accounting for nearly 70% of breast cancers. This presentation aims to provide a brief overview of HR+/HER2- disease management from a nursing perspective in patient management.